Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years

PHASE3CompletedINTERVENTIONAL
Enrollment

3,360

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

October 31, 2013

Conditions
Influenza
Interventions
BIOLOGICAL

Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation

0.1mL, Intradermal

BIOLOGICAL

Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal

0.1mL, Intradermal

BIOLOGICAL

Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal

0.1mL, Intradermal

Trial Locations (38)

13901

Binghamton

14609

Rochester

14621

Rochester

18102

Allentown

19020

Bensalem

29464

Mt. Pleasant

32935

Melbourne

33134

Coral Gables

33143

South Miami

33781

Pinellas Park

35216

Hoover

35802

Huntsville

52242

Iowa City

54449

Marshfield

57049

Dakota Dunes

63104

St Louis

64114

Kansas City

65802

Springfield

66212

Overland Park

67207

Wichita

68134

Omaha

76107

Fort Worth

76135

Fort Worth

76904

San Angelo

78745

Austin

83642

Boise

84088

West Jordan

84109

Salt Lake City

84121

Salt Lake City

85020

Phoenix

85213

Mesa

85224

Chandler

85704

Tucson

91911

Chula Vista

92103

San Diego

95816

Sacramento

06460

Milford

02886

Warwick

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT01712984 - Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years | Biotech Hunter | Biotech Hunter